Ligand Pharmaceuticals

Contributing Author

Recent Articles by Ligand Pharmaceuticals

Nov-06	Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance LGND GlobeNewswire
Oct-30	Ligand to Participate in November Investor Conferences LGND GlobeNewswire
Oct-23	Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025 LGND GlobeNewswire
Oct-16	Ligand to Host Investor Day on December 9, 2025 LGND GlobeNewswire
Oct-09	Ligand Partner SQ Innovation Receives FDA Approval for Lasix ONYU, an At-Home Treatment for Edema in Heart Failure Patients LGND GlobeNewswire
Aug-19	Ligand to Participate in September Investor Conferences LGND GlobeNewswire
Aug-14	Ligand Announces Closing of Convertible Senior Notes Offering LGND GlobeNewswire
Aug-11	Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering LGND GlobeNewswire
Aug-11	Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030 LGND GlobeNewswire
Aug-07	Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance LGND GlobeNewswire
Jul-24	Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025 LGND GlobeNewswire
Jul-10	Ligand Partner Pelthos Therapeutics Launches ZELSUVMI LGND GlobeNewswire
Jul-02	Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics LGND GlobeNewswire
Jun-11	Ligand Announces 2025 Investor Day in New York City LGND GlobeNewswire
May-14	Ligand to Ring the Nasdaq Opening Bell on May 19, 2025 LGND GlobeNewswire
May-08	Ligand Reports First Quarter 2025 Financial Results LGND GlobeNewswire